Lucid Diagnostics (LUCD) Scheduled to Post Quarterly Earnings on Wednesday

Lucid Diagnostics (NASDAQ:LUCD) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.23) earnings per share for the quarter. The business had revenue of $0.98 million for the quarter. On average, analysts expect Lucid Diagnostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lucid Diagnostics Trading Up 4.0 %

Shares of NASDAQ LUCD opened at $1.04 on Friday. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.58. The company has a 50-day moving average of $0.85 and a two-hundred day moving average of $0.84. The company has a market cap of $56.15 million, a PE ratio of -0.85 and a beta of 1.41.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Tuesday, August 13th. Ascendiant Capital Markets dropped their price objective on Lucid Diagnostics from $7.50 to $7.25 and set a “buy” rating for the company in a report on Tuesday, September 10th. Canaccord Genuity Group raised shares of Lucid Diagnostics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, Needham & Company LLC reissued a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research note on Tuesday, August 13th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Lucid Diagnostics has an average rating of “Buy” and an average price target of $3.94.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.